Sweden Reports Rise in Semaglutide Adverse Reactions

Regional networks anchored to local contexts are the missing link for responsible AI in low-resource health systems, a new npj Digital Medicine Perspective argues. #ResponsibleAI #DigitalHealth #GlobalHealth #HealthEquity

The FDA has granted full approval to Inluriyo plus Verzenio for ESR1-mutated metastatic breast cancer. In the Phase 3 EMBER-3 trial, the all-oral combination doubled median progression-free survival versus Inluriyo alone, at 11.1 months versus 5.5 months. #SyenzaNews #Oncology #MarketAccess

HTAsiaLink 2026 brought HTA agencies, researchers and patient representatives together in Taipei to weigh real-world evidence, AI and patient involvement against the realities of different Asia-Pacific health systems. #HTA #HealthEconomics #MarketAccess

Nigeria’s NHIA has inaugurated a national health technology assessment steering committee to anchor healthcare spending in evidence. #SyenzaNews #HTA #HealthEconomics #Nigeria

The European Commission has published three templates that formalise written input from patients, carers and clinicians in EU Joint Clinical Assessments, locking it onto the scope proposal and the draft report. #HTA #JCA #MarketAccess

Portugal pharmaceutical exports climbed 42.9% in 2025 to €5.0 billion. Without that increase, national goods exports would have contracted. #SyenzaNews #MarketAccess #Pharma

Infarmed has launched INOV@INFARMED, a new network connecting Portugal’s medicines regulator with 26 universities and research institutes to advance regulation and health technology assessment. #SyenzaNews #HTA #RegulatoryScience #HealthInnovation

EMA’s CHMP September 2026 meeting ended with positive opinions for 12 new medicines and 11 indication extensions. New approvals cover haemophilia A, ALK-positive lung cancer, myasthenia gravis, ovarian cancer, hidradenitis suppurativa and short bowel syndrome, plus the first biosimilar cleared under the tailored clinical pathway.

#SyenzaNews #pharmaceuticals #drugdevelopment #innovation #MarketAccess

FDA approved finerenone (Kerendia) for CKD associated with type 1 diabetes, the first new treatment for this population in 30 years. The label rests on a six-month UACR reduction, not hard kidney outcomes, so payers and HTA agencies will each have to decide how much credit the surrogate deserves. #SyenzaNews #MarketAccess #CKD #Type1Diabetes

EMEA and GBEI brought China, Malaysia, Japan and India together to map an Asian brain economy strategy, framing brain capital as core economic infrastructure and introducing the Asian Brain Economy Index. #BrainEconomy #BrainCapital #Asia #BrainHealth